The National Institute for Health and Care Excellence (NICE) has recommended the use of teduglutide for the treatment of people with short bowel syndrome (SBS). In a draft guidance published on June 1 ...

Study in adult short bowel syndrome (SBS) patients initiated in June 2020 NM-002 is a long-acting GLP-1 agonist designed to address the gastric effects in SBS patients by slowing digestive transit ...

In the absence of registry data, it is impossible to know the precise incidence and prevalence of short bowel syndrome in the United States. On the basis of European data, the incidence of total ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Stool frequency and consistency improved over 96 weeks ...

Short Bowel Syndrome (SBS) is a multifaceted condition arising from extensive surgical resection of the small intestine, which leads to impaired nutrient absorption and a heightened risk of ...

Zealand Pharma (OTCPK:ZLDPF) said the FDA has declined to approve its drug glepaglutide for the treatment of short bowel syndrome, citing the need for more data. The Danish biotech company had been ...

SATB2 deficiency confers small intestinal (ileal) properties on colon cells. Green fluorescent marker bound to cholesterol (top row) and glucose (bottom row) shows absorption of nutrients in: a) Ileal ...

Please provide your email address to receive an email when new articles are posted on . At 1 year, apraglutide reduced parenteral support volume by 52% in patients with short bowel syndrome with ...

Short Bowel Syndrome (SBS) is a medical disorder caused by a lack of a fully functional small intestine. Whether caused as a birth defect or because part of the small intestine was removed during ...

Short-bowel syndrome (SBS) patients with intestinal failure suffer from malabsorption and usually require long-term parenteral nutrition. It has been suggested that glucagon-like peptide 2 (GLP2), a ...